OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press28610.17650/1818-8346-2018-13-2-32-38HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯVENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)ВЕНЕТОКЛАКС В ЛЕЧЕНИИ ХРОНИЧЕСКОГО ЛИМФОЛЕЙКОЗА (обзор литературы)ByalikT. E.БяликТ. Е.
Russian Federation

23 Kashirskoye Shosse, Moscow 115478

Татьяна Евгеньевна Бялик 

115478 Москва, Каширское шоссе, 23

bialik@bk.ruN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России1207201813232381307201813072018https://oncohematology.abvpress.ru/ongm/article/view/286

In recent years, great progress has been made in understanding biology and pathogenesis of chronic lymphocytic leukemia. The key thing in disease pathogenesis is the apoptosis resistance of tumor cells. One of the main regulators of programmed cell death is the Bcl-2 family proteins. Important role of Bcl-2 protein in carcinogenesis made it an attractive target for therapeutic intervention. This review focuses on venetoclax (a selective inhibitor of the anti-apoptotic Bcl-2 protein) in the treatment of chronic lymphocytic leukemia.

В последние годы достигнуты большие успехи в понимании биологии и механизмов развития хронического лимфолейкоза. Ведущее звено в патогенезе заболевания – резистентность опухолевых клеток к апоптозу. Один из основных регуляторов процессов программированной клеточной гибели – белки семейства Bcl-2. Признание важной роли белка Bcl-2 в развитии опухоли сделало его привлекательной мишенью для терапевтического воздействия. Данный обзор посвящен значению препарата венетоклакс (селективный ингибитор антиапоптотического белка Bcl-2) в лечении хронического лимфолейкоза.

chronic lymphocytic leukemiavenetoclaxхронический лимфолейкозвенетоклакс1. Hallek M., Fischer K., Fingerle-Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164–74. DOI: 10.1016/S0140-6736(10)61381-5. PMID: 20888994.Hallek M., Fischer K., Fingerle-Rowson G. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164–74. DOI: 10.1016/S0140-6736(10)61381-5. PMID: 20888994.2. Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80(4):879–86. PMID: 1498330.Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80(4):879–86. PMID: 1498330.3. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Medicine 1997;3(6):614–620. PMID: 9176486.Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Medicine 1997;3(6):614–620. PMID: 9176486.4. Anderson M.A., Huang D., Roberts A. Targeting BCL2 for the Treatment of Lymphoid Malignancies. Semin Hematol 2014;51(3):219–27. DOI: 10.1053/j.seminhematol.2014.05.008. PMID: 25048785.Anderson M.A., Huang D., Roberts A. Targeting BCL2 for the Treatment of Lymphoid Malignancies. Semin Hematol 2014;51(3):219–27. DOI: 10.1053/j.seminhematol.2014.05.008. PMID: 25048785.5. Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7(12):989–1000. DOI: 10.1038/nrd2658. PMID: 19043450.Lessene G., Czabotar P.E., Colman P.M. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008;7(12):989–1000. DOI: 10.1038/nrd2658. PMID: 19043450.6. Chen L., Willis S.N., Wei A. et al. Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Mol Cell 2005; 17(3):393–403. DOI: 10.1016/j.molcel.2004.12.030. PMID: 15694340.Chen L., Willis S.N., Wei A. et al. Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Mol Cell 2005; 17(3):393–403. DOI: 10.1016/j.molcel.2004.12.030. PMID: 15694340.7. Anderson M.A., Deng J., Seymour J.F. et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016;127(25): 3215–24. DOI: 10.1182/blood-2016-01-688796. PMID: 27069256.Anderson M.A., Deng J., Seymour J.F. et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016;127(25): 3215–24. DOI: 10.1182/blood-2016-01-688796. PMID: 27069256.8. Kim R., Emi M., Matsuura K., Tanabe K. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Therapy 2007;14(1):1–11. DOI: 10.1038/sj.cgt.7700986. PMID: 17041564.Kim R., Emi M., Matsuura K., Tanabe K. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Therapy 2007;14(1):1–11. DOI: 10.1038/sj.cgt.7700986. PMID: 17041564.9. O’Brien S., Moore J.O., Boyd T.E. et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009;27(31):5208–5212. DOI: 10.1200/JCO.2009.22.5748. PMID: 19738118.O’Brien S., Moore J.O., Boyd T.E. et al. 5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009;27(31):5208–5212. DOI: 10.1200/JCO.2009.22.5748. PMID: 19738118.10. Nguyen M., Marcellus R.C., Roulston A. et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007;104(49):19512–17. DOI: 10.1073/pnas.0709443104. PMID: 18040043.Nguyen M., Marcellus R.C., Roulston A. et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007;104(49):19512–17. DOI: 10.1073/pnas.0709443104. PMID: 18040043.11. James D.F., Castro J.E., Loriaat O. et al. AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients with high risk features; preliminary results from an ongoing phase I trial. J Clin Oncol 2006; 24(18 Suppl.):6605. DOI: 10.1200/jco.2006.24.18_suppl.6605.James D.F., Castro J.E., Loriaat O. et al. AT-101, a small molecule Bcl-2 antagonist, in treatment naive CLL patients with high risk features; preliminary results from an ongoing phase I trial. J Clin Oncol 2006; 24(18 Suppl.):6605. DOI: 10.1200/jco.2006.24.18_suppl.6605.12. van Delft M.F., Wei A.H., Mason K.D. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10(5):389–99. DOI: 10.1016/j.ccr.2006.08.027. PMID: 17097561.van Delft M.F., Wei A.H., Mason K.D. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10(5):389–99. DOI: 10.1016/j.ccr.2006.08.027. PMID: 17097561.13. Mason K.D., Vandenberg C.J., Scott C.L. et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008;105(46):17961–17966. DOI: 10.1073/pnas.0809957105. PMID: 19004807.Mason K.D., Vandenberg C.J., Scott C.L. et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008;105(46):17961–17966. DOI: 10.1073/pnas.0809957105. PMID: 19004807.14. Tse C., Shoemaker A.R., Adickes J. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68(9):3421–8. DOI: 10.1158/00085472.CAN-07-5836. PMID: 18451170.Tse C., Shoemaker A.R., Adickes J. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68(9):3421–8. DOI: 10.1158/00085472.CAN-07-5836. PMID: 18451170.15. Roberts A.W., Seymour J.F., Brown J.R. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30(5):488–96. DOI: 10.1200/JCO.2011.34.7898. PMID: 22184378.Roberts A.W., Seymour J.F., Brown J.R. et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30(5):488–96. DOI: 10.1200/JCO.2011.34.7898. PMID: 22184378.16. Wilson W.H., O’Connor O.A., Czuczman M.S. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11(12):1149–59. DOI: 10.1016/S1470-2045(10)70261-8. PMID: 21094089.Wilson W.H., O’Connor O.A., Czuczman M.S. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11(12):1149–59. DOI: 10.1016/S1470-2045(10)70261-8. PMID: 21094089.17. Souers A.J., Leverson J.D., Boghaert E.R. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19(2):202–8. DOI: 10.1038/nm.3048. PMID: 23291630.Souers A.J., Leverson J.D., Boghaert E.R. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19(2):202–8. DOI: 10.1038/nm.3048. PMID: 23291630.18. Seymour J.F., Davids M.S., Pagel J.M. et al. Bcl-2 Inhibitor ABT-199 (GDC0199) Monotherapy Shows AntiTumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood 2013;122(21):872.Seymour J.F., Davids M.S., Pagel J.M. et al. Bcl-2 Inhibitor ABT-199 (GDC0199) Monotherapy Shows AntiTumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood 2013;122(21):872.19. Roberts A.W., Davids M.S., Pagel J.M. et al. The BCL-2 inhibitor ABT-199 (GDC-0199) is active and well-tolerated in ultra-high-risk relapsed/refractory chronic lymphocytic leukemia (CLL). Haematologica 2013;98(Suppl 1):473 (Abstract S1146).Roberts A.W., Davids M.S., Pagel J.M. et al. The BCL-2 inhibitor ABT-199 (GDC-0199) is active and well-tolerated in ultra-high-risk relapsed/refractory chronic lymphocytic leukemia (CLL). Haematologica 2013;98(Suppl 1):473 (Abstract S1146).20. Stilgenbauer S., Eichhorst B., Schetelig J. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016;17(6):768–78. DOI: 10.1016/S1470-2045(16) 30019-5. PMID: 27178240.Stilgenbauer S., Eichhorst B., Schetelig J. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016;17(6):768–78. DOI: 10.1016/S1470-2045(16) 30019-5. PMID: 27178240.21. Stilgenbauer S., Eichhorst B., Schetelig J. et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018; [Epub ahead of print]. DOI: 10.1200/JCO.2017.76.6840. PMID: 29715056.Stilgenbauer S., Eichhorst B., Schetelig J. et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 2018; [Epub ahead of print]. DOI: 10.1200/JCO.2017.76.6840. PMID: 29715056.22. Jones J., Choi M.Y., Mato A.R. et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood 2016;128(22):637.Jones J., Choi M.Y., Mato A.R. et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood 2016;128(22):637.23. Jones J.A., Mato A.R., Wierda W.G. et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018;19(1): 65–75. DOI: 10.1016/S14702045(17)30909-9. PMID: 29246803.Jones J.A., Mato A.R., Wierda W.G. et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018;19(1): 65–75. DOI: 10.1016/S14702045(17)30909-9. PMID: 29246803.24. Brander D.M., Choi M.Y., Roberts A.W. et al. Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood 2016;128(22):2033.Brander D.M., Choi M.Y., Roberts A.W. et al. Detailed Safety Analysis of Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood 2016;128(22):2033.25. Seymour J.F., Kipps T.J., Eichhorstet B.F. et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia – Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood 2017;130(Suppl 1):LBA-2.Seymour J.F., Kipps T.J., Eichhorstet B.F. et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia – Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood 2017;130(Suppl 1):LBA-2.26. Flinn I.W., Gribben J.G., Dyer M.J.S. et al. Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia – Results from a Phase 1b Study (GP28331). Blood 2017;130(Suppl 1):430.Flinn I.W., Gribben J.G., Dyer M.J.S. et al. Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia – Results from a Phase 1b Study (GP28331). Blood 2017;130(Suppl 1):430.27. Fischer K., Al-Sawaf O., Fink A.M. et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood 2017;129(19):2702–5. DOI: 10.1182/blood-2017-01-761973. PMID: 28325865.Fischer K., Al-Sawaf O., Fink A.M. et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood 2017;129(19):2702–5. DOI: 10.1182/blood-2017-01-761973. PMID: 28325865.28. Cramer Р., von Tresckow J., Bahlo J. et al. Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the german CLL study group (GCLLSG). Hematol Oncol 2017;35(Suppl 2):25–7. DOI: 10.1002/hon.2437_5.Cramer Р., von Tresckow J., Bahlo J. et al. Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the german CLL study group (GCLLSG). Hematol Oncol 2017;35(Suppl 2):25–7. DOI: 10.1002/hon.2437_5.29. Jain N., Thompson P.A., Ferrajoli A. et al. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood 2017;130(Suppl 1):429.Jain N., Thompson P.A., Ferrajoli A. et al. Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial. Blood 2017;130(Suppl 1):429.30. Hillmen P., Munir T., Rawstron A. et al. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Blood 2017;130(Suppl 1):428.Hillmen P., Munir T., Rawstron A. et al. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Blood 2017;130(Suppl 1):428.31. Eichhorst B., Robak T., Montserrat P. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(Suppl 5):v78–v4. DOI: 10.1093/annonc/mdv303. PMID: 26314781.Eichhorst B., Robak T., Montserrat P. et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26(Suppl 5):v78–v4. DOI: 10.1093/annonc/mdv303. PMID: 26314781.32. Mato A.R., Hill B.T., Lamanna N. et al. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. Blood 2016;128(22):4400.Mato A.R., Hill B.T., Lamanna N. et al. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. Blood 2016;128(22):4400.33. Mauro F.R., Foà R. Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib. Lancet Oncol 2018;19(1):7–8. DOI: 10.1016/S1470-2045(17)30910-5. PMID: 29246804.Mauro F.R., Foà R. Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib. Lancet Oncol 2018;19(1):7–8. DOI: 10.1016/S1470-2045(17)30910-5. PMID: 29246804.